Vemurafenib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With BRAF V600 Mutations (A Pediatric MATCH Treatment Trial)
NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice) Screening Protocol
-
Clinical Trial Information
Trial Contact: Spinelli, Jennifer; Leffin, Melissa; El-Shami, Jessica
Trial Phone: 321.841.5357 ; 321.841.2008 ; 321.841.3837
-
IRB No: APEC1621G
Protocol Abbrev: APEC1621G
Principal Investigator: Amy A Smith, MD
Phase: Drug: Phase II
Age Group: Pediatric
Secondary Protocol No: APEC1621G
Treatment: vemurafenib
Therapies Involved: Chemotherapy
ClinicalTrials.gov ID: NCT03220035
-
Objective
To determine the objective response rate (ORR; complete response + partial response) in pediatric patients treated with vemurafenib with advanced solid tumors (including central nervous system [CNS] tumors), lymphomas or histiocytic disorders that harbor activating BRAF V600 mutations.
-
Key Eligibility
Inclusion Criteria:
Ages Eligible for Study: 12 Months to 21 Years (Child, Adult)
Sexes Eligible for Study: All
Accepts Healthy Volunteers: No
